M&A Deal Summary

Novartis Acquires MorphoSys

On February 5, 2024, Novartis acquired life science company MorphoSys for 2.7B EUR

Acquisition Highlights
  • This is Novartis’ 26th transaction in the Life Science sector.
  • This is Novartis’ 3rd largest (disclosed) transaction.
  • This is Novartis’ 1st transaction in Germany.

M&A Deal Summary
Date 2024-02-05
Target MorphoSys
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition
Deal Value 2.7B EUR

Target

MorphoSys

Planegg, Germany
website
MorphoSys is a global biopharmaceutical company developing innovative medicines in oncology. MorphoSys was formed in 1992 and is based in Planegg, Germany.

Search 193,092 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland

website

Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 51.8B USD (2022)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 31 of 32
Sector (Life Science) 26 of 26
Type (Add-on Acquisition) 27 of 28
Country (Germany) 1 of 1
Year (2024) 2 of 3
Size (of disclosed) 3 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-01-05 SanReno Therapeutics

Shanghai, China

SanReno Therapeutics is a clinical-stage enterprise specializing in the strategic development, exploration, and commercialization of revolutionary therapies tailored for kidney diseases. The company's key assets focus on treating Immunoglobulin A Nephropathy (IgAN). Atrasentan, an oral endothelian A receptor antagonist (ERA), has reached Phase 3 with success in reducing proteinuria. Zigakibart, its anti-APRIL (A Proliferation Inducing Ligand) antibody, received regulatory approval for Phase 3 studies. SanReno Therapeutics is based in Shanghai.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-02 Mariana Oncology

Watertown, Massachusetts, United States

Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana Oncology is based in Watertown, Massachusetts.

Buy $1.0B
Mergr

Product

Company

Legal